Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedNew revision entry 'Revision: v3.3.3' was added. 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed from the deletions list.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 along with government funding notices; these changes update site metadata rather than the study details.SummaryDifference0.3%

- Check59 days agoChange DetectedNew version entries in the record history show updated study and recruitment statuses for NCT03976362.SummaryDifference0.0%

- Check73 days agoChange DetectedMinor updates: added a new date (2025-10-16) and a study status line (IPDSharing) for 2025-10-07, while removing an older date (2025-01-16).SummaryDifference0.7%

- Check88 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference7%

- Check95 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.